Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
The University of Texas MD Anderson Cancer Center · University of Milan · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
118
total citations
- FWCI
- 29.58
- Percentile
- 100%
- References
- 29
Citations per year
Authors
26- KRKanwal RaghavCorresponding
The University of Texas MD Anderson Cancer Center
- SSSalvatore Siena
University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- ATAtsuo Takashima
National Cancer Center Hospital East
- TKTakeshi Kato
Osaka National Hospital
- MVMarc Van den Eynde
Cliniques Universitaires Saint-Luc
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Internal medicine
- Colorectal cancer
- Oncology
- Clinical endpoint
- Refractory (planetary science)
- Chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.